Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort. (27th July 2016)
- Record Type:
- Journal Article
- Title:
- Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort. (27th July 2016)
- Main Title:
- Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort
- Authors:
- Balagopal, Ashwin
Gupte, Nikhil
Shivakoti, Rupak
Cox, Andrea L.
Yang, Wei-Teng
Berendes, Sima
Mwelase, Noluthando
Kanyama, Cecilia
Pillay, Sandy
Samaneka, Wadzanai
Santos, Breno
Poongulali, Selvamuthu
Tripathy, Srikanth
Riviere, Cynthia
Lama, Javier R.
Cardoso, Sandra W.
Sugandhavesa, Patcharaphan
Semba, Richard D.
Hakim, James
Hosseinipour, Mina C.
Kumarasamy, Nagalingeswaran
Sanne, Ian
Asmuth, David
Campbell, Thomas
Bollinger, Robert C.
Gupta, Amita - Abstract:
- Abstract: Background. We assessed immune activation after antiretroviral therapy (ART) initiation to understand clinical failure in diverse settings. Methods. We performed a case-control study in ACTG Prospective Evaluation of Antiretrovirals in Resource-Limited Settings (PEARLS). Cases were defined as incident World Health Organization Stage 3 or 4 human immunodeficiency virus (HIV) disease or death, analyzed from ART weeks 24 (ART24) to 96. Controls were randomly selected. Interleukin (IL)-6, interferon (IFN)-γ-inducible protein-10, IL-18, tumor necrosis factor-α, IFN-γ, and soluble CD14 (sCD14) were measured pre-ART and at ART24 in plasma. Continued elevation was defined by thresholds set by highest pre-ART quartiles (>Q3). Incident risk ratios (IRRs) for clinical progression were estimated by Poisson regression, adjusting for age, sex, treatment, country, time-updated CD4 + T-cell count, HIV ribonucleic acid (RNA), and prevalent tuberculosis. Results. Among 99 cases and 234 controls, median baseline CD4 + T-cell count was 181 cells/µL, and HIV RNA was 5.05 log10 cp/mL. Clinical failure was independently associated with continued elevations of IL-18 (IRR, 3.03; 95% confidence interval [CI], 1.27–7.20), sCD14 (IRR, 2.17; 95% CI, 1.02–4.62), and IFN-γ (IRR, 0.08; 95% CI, 0.01–0.61). Among 276 of 333 (83%) who were virologically suppressed at ART24, IFN-γ was associated with protection from failure, but the association with sCD14 was attenuated. Conclusions. ContinuedAbstract: Background. We assessed immune activation after antiretroviral therapy (ART) initiation to understand clinical failure in diverse settings. Methods. We performed a case-control study in ACTG Prospective Evaluation of Antiretrovirals in Resource-Limited Settings (PEARLS). Cases were defined as incident World Health Organization Stage 3 or 4 human immunodeficiency virus (HIV) disease or death, analyzed from ART weeks 24 (ART24) to 96. Controls were randomly selected. Interleukin (IL)-6, interferon (IFN)-γ-inducible protein-10, IL-18, tumor necrosis factor-α, IFN-γ, and soluble CD14 (sCD14) were measured pre-ART and at ART24 in plasma. Continued elevation was defined by thresholds set by highest pre-ART quartiles (>Q3). Incident risk ratios (IRRs) for clinical progression were estimated by Poisson regression, adjusting for age, sex, treatment, country, time-updated CD4 + T-cell count, HIV ribonucleic acid (RNA), and prevalent tuberculosis. Results. Among 99 cases and 234 controls, median baseline CD4 + T-cell count was 181 cells/µL, and HIV RNA was 5.05 log10 cp/mL. Clinical failure was independently associated with continued elevations of IL-18 (IRR, 3.03; 95% confidence interval [CI], 1.27–7.20), sCD14 (IRR, 2.17; 95% CI, 1.02–4.62), and IFN-γ (IRR, 0.08; 95% CI, 0.01–0.61). Among 276 of 333 (83%) who were virologically suppressed at ART24, IFN-γ was associated with protection from failure, but the association with sCD14 was attenuated. Conclusions. Continued IL-18 and sCD14 elevations were associated with clinical ART failure. Interferon-γ levels may reflect preserved immune function. … (more)
- Is Part Of:
- Open forum infectious diseases. Volume 3:Number 3(2016)
- Journal:
- Open forum infectious diseases
- Issue:
- Volume 3:Number 3(2016)
- Issue Display:
- Volume 3, Issue 3 (2016)
- Year:
- 2016
- Volume:
- 3
- Issue:
- 3
- Issue Sort Value:
- 2016-0003-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2016-07-27
- Subjects:
- antiretroviral therapy -- HIV -- IFN-γ -- inflammasome -- IL-18 -- immune activation
Communicable diseases -- Periodicals
Medical microbiology -- Periodicals
Infection -- Periodicals
616.9 - Journal URLs:
- http://ofid.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/en/ ↗ - DOI:
- 10.1093/ofid/ofw118 ↗
- Languages:
- English
- ISSNs:
- 2328-8957
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20861.xml